Loading stock data…
Inogen, Inc (INGN)
$5.23-0.19 (-3.51%)
Market ClosedLast close Sep 8
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Inogen, Inc. in the Healthcare sector is trading at $5.23 with a market capitalization of $139M. Wall Street consensus targets $12.00 (2 analysts), implying a +129.4% move over the next 12 months. The stock is currently near its 52-week low of $5.20, remaining 18.3% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +129.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 33) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $85.11M↑ | $81.72M↓ | $92.39M↑ | $92.28M |
| Gross Profit | — | $37.86M↑ | $35.24M↓ | $41.32M | $41.34M |
| Operating Income | — | -$9.34M↓ | -$9.31M↓ | -$7.12M↓ | -$6.13M |
| Net Income | — | -$8.32M↓ | -$7.13M↓ | -$5.29M↓ | -$4.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen thera...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$138.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.07%
Volume
Today's trading volume
316,254
Recent News
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
INGN's POC demand, new products and international growth support its outlook, while U.S. channel shifts and distributor timing pose risks.
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
Inogen (INGN) Cuts Guidance Even As Profitability Climbs
On August 6, Inogen (NASDAQ:INGN) reported second-quarter results that captured the company’s split personality right now. International sales keep compounding, new products are finding buyers, and profitability is improving. But the US business is still losing ground to a structural shift in how patients get oxygen therapy, and that weakness was enough to push full-year […]
Inogen (INGN) Q2 2026 Earnings Call Transcript
International sales surged 14.8% as new product categories expanded the addressable market.
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
INGN cuts its 2026 revenue outlook as U.S. channel pressure weighs, while international growth, new products and cost control offer support.